Lutetium Lu 177-DOTA
Term · Oncology and biomedicine · MLC-T-ONC-014928
A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation.
| Identifier | MLC-T-ONC-014928 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | 177Lu-DOTA; 177Lu-labeled DOTA; Lu-177-DOTA |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014928",
"term": "Lutetium Lu 177-DOTA",
"field": "Oncology and biomedicine",
"definition": "A radioconjugate composed of the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) labeled with the beta-emitting isotope lutetium Lu 177 (Lu-177), that can be used for radioimmunotherapeutic purposes. Upon administration, Lu-177-DOTA may act as a hapten for pretargeted radioimmunotherapy, and delivers targeted beta radiation.",
"synonyms": [
"177Lu-DOTA",
"177Lu-labeled DOTA",
"Lu-177-DOTA"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-dota/"
}
Record 10,410 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.